<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Oral Anticoagulation Quick Reference</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        :root {
            --primary: #2c3e50;
            --secondary: #3498db;
            --success: #27ae60;
            --warning: #f39c12;
            --danger: #e74c3c;
            --light: #ecf0f1;
            --dark: #2c3e50;
            --neutral: #7f8c8d;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
        }

        body {
            background-color: #f8f9fa;
            color: #333;
            line-height: 1.6;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 0 15px;
        }

        header {
            background: linear-gradient(135deg, var(--primary), var(--secondary));
            color: white;
            padding: 15px 0;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
            position: sticky;
            top: 0;
            z-index: 100;
        }

        .header-content {
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .logo {
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .logo i {
            font-size: 28px;
        }

        .logo h1 {
            font-size: 24px;
            font-weight: 600;
        }

        .last-updated {
            font-size: 14px;
            opacity: 0.9;
        }

        .nav-tabs {
            display: flex;
            background-color: white;
            border-bottom: 1px solid #ddd;
            overflow-x: auto;
            margin-bottom: 20px;
        }

        .nav-tab {
            padding: 12px 20px;
            cursor: pointer;
            border-bottom: 3px solid transparent;
            transition: all 0.3s ease;
            white-space: nowrap;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .nav-tab:hover {
            background-color: #f5f5f5;
        }

        .nav-tab.active {
            border-bottom: 3px solid var(--secondary);
            font-weight: 600;
            color: var(--secondary);
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }

        .tab-content.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .alert {
            padding: 15px;
            margin-bottom: 20px;
            border-radius: 5px;
            display: flex;
            align-items: flex-start;
            gap: 10px;
        }

        .alert-danger {
            background-color: #f8d7da;
            border-left: 5px solid var(--danger);
            color: #721c24;
        }

        .alert-success {
            background-color: #d4edda;
            border-left: 5px solid var(--success);
            color: #155724;
        }

        .alert-info {
            background-color: #d1ecf1;
            border-left: 5px solid var(--secondary);
            color: #0c5460;
        }

        .card-container {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 30px;
        }

        .card {
            background-color: white;
            border-radius: 8px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.05);
            padding: 20px;
            transition: transform 0.3s ease, box-shadow 0.3s ease;
            height: 100%;
        }

        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 10px;
            margin-bottom: 15px;
            padding-bottom: 10px;
            border-bottom: 1px solid #eee;
        }

        .card-header i {
            font-size: 20px;
        }

        .card-title {
            font-size: 18px;
            font-weight: 600;
        }

        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin-bottom: 30px;
        }

        .info-table {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 20px;
        }

        .info-table th, .info-table td {
            padding: 12px 15px;
            text-align: left;
            border-bottom: 1px solid #ddd;
        }

        .info-table th {
            background-color: #f2f2f2;
            font-weight: 600;
        }

        .info-table tr:hover {
            background-color: #f5f5f5;
        }

        .action-button {
            display: inline-block;
            padding: 10px 15px;
            border-radius: 5px;
            color: white;
            text-decoration: none;
            transition: background-color 0.3s;
            cursor: pointer;
            border: none;
            font-size: 14px;
            margin-right: 10px;
            margin-bottom: 10px;
        }

        .action-button:hover {
            opacity: 0.9;
        }

        .btn-danger {
            background-color: var(--danger);
        }

        .btn-success {
            background-color: var(--success);
        }

        .btn-info {
            background-color: var(--secondary);
        }

        .btn-neutral {
            background-color: var(--neutral);
        }

        .emergency-banner {
            background-color: var(--danger);
            color: white;
            padding: 15px;
            border-radius: 5px;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 15px;
            animation: pulse 2s infinite;
        }

        @keyframes pulse {
            0% { box-shadow: 0 0 0 0 rgba(231, 76, 60, 0.4); }
            70% { box-shadow: 0 0 0 10px rgba(231, 76, 60, 0); }
            100% { box-shadow: 0 0 0 0 rgba(231, 76, 60, 0); }
        }

        .emergency-banner i {
            font-size: 24px;
        }

        .quick-ref {
            background-color: white;
            border-radius: 8px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.05);
            padding: 20px;
            margin-bottom: 20px;
        }

        .quick-ref-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 15px;
            padding-bottom: 10px;
            border-bottom: 1px solid #eee;
        }

        .quick-ref-title {
            font-size: 18px;
            font-weight: 600;
            color: var(--primary);
        }

        .quick-ref-content {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(200px, 1fr));
            gap: 15px;
        }

        .quick-ref-item {
            padding: 10px;
            border-radius: 5px;
            transition: background-color 0.3s;
        }

        .quick-ref-item:hover {
            background-color: #f5f5f5;
        }

        .tag {
            display: inline-block;
            padding: 3px 8px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: 600;
            margin-right: 5px;
        }

        .tag-danger {
            background-color: rgba(231, 76, 60, 0.2);
            color: var(--danger);
        }

        .tag-success {
            background-color: rgba(39, 174, 96, 0.2);
            color: var(--success);
        }

        .tag-info {
            background-color: rgba(52, 152, 219, 0.2);
            color: var(--secondary);
        }

        .tag-neutral {
            background-color: rgba(127, 140, 141, 0.2);
            color: var(--neutral);
        }

        .footer {
            background-color: var(--primary);
            color: white;
            padding: 20px 0;
            margin-top: 40px;
        }

        .footer-content {
            display: flex;
            justify-content: space-between;
            flex-wrap: wrap;
        }

        .footer-section {
            flex: 1;
            min-width: 200px;
            margin-bottom: 20px;
        }

        .footer-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 10px;
        }

        .footer-links {
            list-style: none;
        }

        .footer-links li {
            margin-bottom: 5px;
        }

        .footer-links a {
            color: #ddd;
            text-decoration: none;
            transition: color 0.3s;
        }

        .footer-links a:hover {
            color: white;
        }

        .copyright {
            text-align: center;
            padding-top: 20px;
            border-top: 1px solid rgba(255,255,255,0.1);
            font-size: 14px;
        }

        .search-box {
            position: relative;
            margin-bottom: 20px;
        }

        .search-box input {
            width: 100%;
            padding: 12px 40px 12px 15px;
            border: 1px solid #ddd;
            border-radius: 5px;
            font-size: 16px;
        }

        .search-box i {
            position: absolute;
            right: 15px;
            top: 50%;
            transform: translateY(-50%);
            color: var(--neutral);
        }

        .collapsible {
            background-color: white;
            border: 1px solid #ddd;
            border-radius: 5px;
            margin-bottom: 10px;
            overflow: hidden;
        }

        .collapsible-header {
            padding: 15px;
            background-color: #f2f2f2;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            transition: background-color 0.3s;
        }

        .collapsible-header:hover {
            background-color: #eaeaea;
        }

        .collapsible-header i {
            transition: transform 0.3s;
        }

        .collapsible.active .collapsible-header i {
            transform: rotate(180deg);
        }

        .collapsible-content {
            padding: 0 15px;
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease-out, padding 0.3s;
        }

        .collapsible.active .collapsible-content {
            padding: 15px;
            max-height: 1000px;
        }

        .drug-comparison {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 20px;
        }

        .drug-comparison th, .drug-comparison td {
            padding: 12px 15px;
            text-align: left;
            border: 1px solid #ddd;
        }

        .drug-comparison th {
            background-color: #f2f2f2;
            font-weight: 600;
        }

        .drug-comparison tr:nth-child(even) {
            background-color: #f9f9f9;
        }

        .drug-comparison tr:hover {
            background-color: #f5f5f5;
        }

        @media (max-width: 768px) {
            .two-column {
                grid-template-columns: 1fr;
            }
            
            .card-container {
                grid-template-columns: 1fr;
            }
            
            .footer-content {
                flex-direction: column;
            }
            
            .quick-ref-content {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <header>
        <div class="container">
            <div class="header-content">
                <div class="logo">
                    <i class="fas fa-pills"></i>
                    <h1>Oral Anticoagulation Quick Reference</h1>
                </div>
                <div class="last-updated">
                    <i class="fas fa-calendar-alt"></i> Last updated: August 2025
                </div>
            </div>
        </div>
    </header>

    <div class="container">
        <div class="nav-tabs">
            <div class="nav-tab active" onclick="openTab('overview')">
                <i class="fas fa-home"></i> Overview
            </div>
            <div class="nav-tab" onclick="openTab('apixaban')">
                <i class="fas fa-capsules"></i> Apixaban
            </div>
            <div class="nav-tab" onclick="openTab('dabigatran')">
                <i class="fas fa-capsules"></i> Dabigatran
            </div>
            <div class="nav-tab" onclick="openTab('edoxaban')">
                <i class="fas fa-capsules"></i> Edoxaban
            </div>
            <div class="nav-tab" onclick="openTab('rivaroxaban')">
                <i class="fas fa-capsules"></i> Rivaroxaban
            </div>
            <div class="nav-tab" onclick="openTab('warfarin')">
                <i class="fas fa-capsules"></i> Warfarin
            </div>
            <div class="nav-tab" onclick="openTab('emergency')">
                <i class="fas fa-exclamation-triangle"></i> Emergency
            </div>
        </div>

        <div id="overview" class="tab-content active">
            <div class="emergency-banner">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>CRITICAL REMINDER:</strong> Always assess bleeding risk before initiating or continuing anticoagulation. Consider HAS-BLED score for AF patients.
                </div>
            </div>

            <div class="search-box">
                <input type="text" placeholder="Search for drug interactions, dosing, or contraindications...">
                <i class="fas fa-search"></i>
            </div>

            <div class="card-container">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-info-circle" style="color: var(--secondary);"></i>
                        <h3 class="card-title">Anticoagulants Overview</h3>
                    </div>
                    <p>Oral anticoagulants are used to prevent thrombus formation or extension of existing thrombus in the venous circulation. Two main types:</p>
                    <ul>
                        <li><strong>Vitamin K antagonists (VKAs):</strong> Warfarin</li>
                        <li><strong>Direct oral anticoagulants (DOACs):</strong> Apixaban, Dabigatran, Edoxaban, Rivaroxaban</li>
                    </ul>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-exclamation-triangle" style="color: var(--danger);"></i>
                        <h3 class="card-title">Red Flags</h3>
                    </div>
                    <ul>
                        <li>Active clinically significant bleeding</li>
                        <li>CrCl &lt; 15 mL/min (for DOACs)</li>
                        <li>Severe hepatic impairment with coagulopathy</li>
                        <li>Antiphospholipid syndrome (DOACs)</li>
                        <li>Prosthetic heart valves (DOACs)</li>
                    </ul>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-check-circle" style="color: var(--success);"></i>
                        <h3 class="card-title">Safe Practices</h3>
                    </div>
                    <ul>
                        <li>Regular monitoring of renal function</li>
                        <li>Review for drug interactions</li>
                        <li>Assess bleeding risk regularly</li>
                        <li>Patient education on signs of bleeding</li>
                        <li>Consider dose adjustments in elderly/frail</li>
                    </ul>
                </div>
            </div>

            <div class="quick-ref">
                <div class="quick-ref-header">
                    <h3 class="quick-ref-title">Quick Drug Comparison</h3>
                </div>
                <table class="drug-comparison">
                    <thead>
                        <tr>
                            <th>Drug</th>
                            <th>Target</th>
                            <th>Renal Adjustment</th>
                            <th>Monitoring</th>
                            <th>Reversal Agent</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Apixaban</td>
                            <td>Factor Xa</td>
                            <td>CrCl 15-29 mL/min</td>
                            <td>4-6 monthly</td>
                            <td>Andexanet alfa</td>
                        </tr>
                        <tr>
                            <td>Dabigatran</td>
                            <td>Thrombin</td>
                            <td>CrCl 30-50 mL/min</td>
                            <td>4-6 monthly</td>
                            <td>Idarucizumab</td>
                        </tr>
                        <tr>
                            <td>Edoxaban</td>
                            <td>Factor Xa</td>
                            <td>CrCl 15-50 mL/min</td>
                            <td>4-6 monthly</td>
                            <td>Andexanet alfa</td>
                        </tr>
                        <tr>
                            <td>Rivaroxaban</td>
                            <td>Factor Xa</td>
                            <td>CrCl 15-50 mL/min</td>
                            <td>4-6 monthly</td>
                            <td>Andexanet alfa</td>
                        </tr>
                        <tr>
                            <td>Warfarin</td>
                            <td>Vitamin K</td>
                            <td>No adjustment</td>
                            <td>Regular INR</td>
                            <td>Vitamin K, PCC</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="two-column">
                <div class="quick-ref">
                    <div class="quick-ref-header">
                        <h3 class="quick-ref-title">Common Indications</h3>
                    </div>
                    <div class="quick-ref-content">
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-heartbeat" style="color: var(--danger);"></i> Atrial Fibrillation</h4>
                            <p>Prevention of stroke and systemic embolism in NVAF with CHA₂DS₂-VASc ≥ 2</p>
                        </div>
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-lungs" style="color: var(--secondary);"></i> Pulmonary Embolism</h4>
                            <p>Treatment and prevention of recurrent PE</p>
                        </div>
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-venus" style="color: var(--secondary);"></i> Deep Vein Thrombosis</h4>
                            <p>Treatment and prevention of recurrent DVT</p>
                        </div>
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-bone" style="color: var(--neutral);"></i> Orthopedic Surgery</h4>
                            <p>VTE prophylaxis after hip/knee replacement</p>
                        </div>
                    </div>
                </div>

                <div class="quick-ref">
                    <div class="quick-ref-header">
                        <h3 class="quick-ref-title">Monitoring Requirements</h3>
                    </div>
                    <div class="quick-ref-content">
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-user-clock" style="color: var(--info);"></i> DOACs</h4>
                            <p>4-6 monthly for ≥75 years or frail patients; 6-12 monthly for others</p>
                        </div>
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-tint" style="color: var(--danger);"></i> Warfarin</h4>
                            <p>Regular INR monitoring (target 2-3 for most indications)</p>
                        </div>
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-kidney" style="color: var(--secondary);"></i> Renal Function</h4>
                            <p>Check at least annually, more frequently in elderly or if deteriorating</p>
                        </div>
                        <div class="quick-ref-item">
                            <h4><i class="fas fa-liver" style="color: var(--secondary);"></i> Liver Function</h4>
                            <p>Check if clinically indicated, especially with DOACs</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Key Drug Interactions</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>Strong Interactions (Avoid or Use with Caution)</h4>
                            <ul>
                                <li><strong>NSAIDs:</strong> Increased bleeding risk with all anticoagulants</li>
                                <li><strong>Strong CYP3A4/P-gp Inhibitors:</strong> Increase DOAC levels (e.g., ketoconazole, ritonavir)</li>
                                <li><strong>Strong CYP3A4/P-gp Inducers:</strong> Decrease DOAC levels (e.g., rifampicin, carbamazepine)</li>
                                <li><strong>Antiplatelets:</strong> Increased bleeding risk</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Special Considerations</h4>
                            <ul>
                                <li><strong>Antibiotics:</strong> May affect warfarin metabolism</li>
                                <li><strong>SSRIs/SNRIs:</strong> Possible increased bleeding risk</li>
                                <li><strong>Amiodarone:</strong> Increases apixaban levels (no dose adjustment needed)</li>
                                <li><strong>Verapamil/Diltiazem:</strong> Increase apixaban levels (no dose adjustment needed)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div id="apixaban" class="tab-content">
            <div class="alert alert-danger">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>CONTRAINDICATED:</strong> CrCl &lt; 15 mL/min, significant liver disease with coagulopathy, prosthetic heart valves, antiphospholipid syndrome, active clinically significant bleeding.
                </div>
            </div>

            <div class="two-column">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-prescription-bottle-alt" style="color: var(--success);"></i>
                        <h3 class="card-title">Dosing Information</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Indication</th>
                            <th>Dose</th>
                        </tr>
                        <tr>
                            <td>NVAF Stroke Prevention</td>
                            <td>5mg twice daily</td>
                        </tr>
                        <tr>
                            <td>NVAF (Reduced Dose)</td>
                            <td>2.5mg twice daily if ≥2 of: age ≥80, weight ≤60kg, Cr ≥133µmol/L</td>
                        </tr>
                        <tr>
                            <td>DVT/PE Treatment</td>
                            <td>10mg twice daily ×7 days, then 5mg twice daily</td>
                        </tr>
                        <tr>
                            <td>Recurrent DVT/PE Prevention</td>
                            <td>2.5mg twice daily (after ≥6 months treatment)</td>
                        </tr>
                        <tr>
                            <td>Hip Replacement</td>
                            <td>2.5mg twice daily for 32-38 days</td>
                        </tr>
                        <tr>
                            <td>Knee Replacement</td>
                            <td>2.5mg twice daily for 10-14 days</td>
                        </tr>
                    </table>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-exclamation-triangle" style="color: var(--warning);"></i>
                        <h3 class="card-title">Adverse Effects</h3>
                    </div>
                    <ul>
                        <li><strong>Common:</strong> Bleeding, anemia, bruising, nausea, skin reactions</li>
                        <li><strong>Uncommon:</strong> Hypersensitivity, thrombocytopenia, deranged LFTs</li>
                        <li><strong>Rare:</strong> Angioedema, cutaneous vasculitis, anticoagulant-related nephropathy</li>
                    </ul>
                    <div class="alert alert-info">
                        <i class="fas fa-info-circle"></i>
                        <div>
                            <strong>REVERSAL:</strong> Andexanet alfa (Ondexxya®) for life-threatening or uncontrolled bleeding.
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Key Drug Interactions</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>Avoid With</h4>
                            <ul>
                                <li>Strong CYP3A4/P-gp inhibitors (itraconazole, ketoconazole, ritonavir)</li>
                                <li>Other anticoagulants (except when switching)</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Use With Caution</h4>
                            <ul>
                                <li>NSAIDs (increased bleeding risk)</li>
                                <li>Antiplatelets (increased bleeding risk)</li>
                                <li>Strong CYP3A4/P-gp inducers (reduced efficacy)</li>
                                <li>SSRIs/SNRIs (possible increased bleeding)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Switching Anticoagulants</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>From Warfarin to Apixaban</h4>
                            <ul>
                                <li>Stop warfarin and measure INR</li>
                                <li>If INR &lt; 2: Start apixaban</li>
                                <li>If INR 2-2.5: Start apixaban immediately or next day</li>
                                <li>If INR &gt; 2.5: Wait until INR &lt; 2</li>
                            </ul>
                        </div>
                        <div>
                            <h4>From Apixaban to Warfarin</h4>
                            <ul>
                                <li>Start warfarin but continue apixaban</li>
                                <li>After ≥2 days of concurrent therapy, measure INR before next apixaban dose</li>
                                <li>If INR in target range: Stop apixaban</li>
                                <li>If INR not in target range: Continue both until INR in range</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div id="dabigatran" class="tab-content">
            <div class="alert alert-danger">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>CONTRAINDICATED:</strong> CrCl &lt; 30 mL/min, significant liver disease with coagulopathy, prosthetic heart valves, antiphospholipid syndrome, active clinically significant bleeding.
                </div>
            </div>

            <div class="two-column">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-prescription-bottle-alt" style="color: var(--success);"></i>
                        <h3 class="card-title">Dosing Information</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Indication</th>
                            <th>Dose</th>
                        </tr>
                        <tr>
                            <td>NVAF Stroke Prevention</td>
                            <td>150mg twice daily</td>
                        </tr>
                        <tr>
                            <td>NVAF (Reduced Dose)</td>
                            <td>110mg twice daily if age ≥80, high bleeding risk, or CrCl 30-50 mL/min</td>
                        </tr>
                        <tr>
                            <td>DVT/PE Treatment</td>
                            <td>150mg twice daily after ≥5 days parenteral anticoagulant</td>
                        </tr>
                        <tr>
                            <td>Recurrent DVT/PE Prevention</td>
                            <td>150mg twice daily (after ≥6 months treatment)</td>
                        </tr>
                        <tr>
                            <td>Hip/Knee Replacement</td>
                            <td>110mg within 1-4 hours post-surgery, then 220mg once daily</td>
                        </tr>
                    </table>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-exclamation-triangle" style="color: var(--warning);"></i>
                        <h3 class="card-title">Adverse Effects</h3>
                    </div>
                    <ul>
                        <li><strong>Common:</strong> Bleeding, anemia, GI upset, dyspepsia</li>
                        <li><strong>Uncommon:</strong> Hypersensitivity, thrombocytopenia, deranged LFTs</li>
                        <li><strong>Rare:</strong> Angioedema, anticoagulant-related nephropathy</li>
                    </ul>
                    <div class="alert alert-info">
                        <i class="fas fa-info-circle"></i>
                        <div>
                            <strong>REVERSAL:</strong> Idarucizumab (Praxbind®) for life-threatening or uncontrolled bleeding.
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Key Drug Interactions</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>Avoid With</h4>
                            <ul>
                                <li>Strong P-gp inhibitors (ketoconazole, dronedarone)</li>
                                <li>Other anticoagulants (except when switching)</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Use With Caution</h4>
                            <ul>
                                <li>NSAIDs (increased bleeding risk)</li>
                                <li>Antiplatelets (increased bleeding risk)</li>
                                <li>Strong P-gp inducers (reduced efficacy)</li>
                                <li>SSRIs/SNRIs (possible increased bleeding)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div id="edoxaban" class="tab-content">
            <div class="alert alert-danger">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>CONTRAINDICATED:</strong> CrCl &lt; 15 mL/min, significant liver disease with coagulopathy, prosthetic heart valves, antiphospholipid syndrome, active clinically significant bleeding.
                </div>
            </div>

            <div class="two-column">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-prescription-bottle-alt" style="color: var(--success);"></i>
                        <h3 class="card-title">Dosing Information</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Indication</th>
                            <th>Dose</th>
                        </tr>
                        <tr>
                            <td>NVAF Stroke Prevention</td>
                            <td>60mg once daily</td>
                        </tr>
                        <tr>
                            <td>NVAF (Reduced Dose)</td>
                            <td>30mg once daily if any of: weight ≤60kg, CrCl 15-50 mL/min, concomitant certain P-gp inhibitors</td>
                        </tr>
                        <tr>
                            <td>DVT/PE Treatment</td>
                            <td>60mg once daily after ≥5 days parenteral anticoagulant</td>
                        </tr>
                        <tr>
                            <td>Recurrent DVT/PE Prevention</td>
                            <td>60mg once daily (after ≥6 months treatment)</td>
                        </tr>
                    </table>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-exclamation-triangle" style="color: var(--warning);"></i>
                        <h3 class="card-title">Adverse Effects</h3>
                    </div>
                    <ul>
                        <li><strong>Common:</strong> Bleeding, anemia, rash</li>
                        <li><strong>Uncommon:</strong> Hypersensitivity, thrombocytopenia, deranged LFTs</li>
                        <li><strong>Rare:</strong> Anticoagulant-related nephropathy</li>
                    </ul>
                    <div class="alert alert-info">
                        <i class="fas fa-info-circle"></i>
                        <div>
                            <strong>REVERSAL:</strong> Andexanet alfa (Ondexxya®) for life-threatening or uncontrolled bleeding.
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Key Drug Interactions</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>Avoid With</h4>
                            <ul>
                                <li>Strong P-gp inhibitors (ketoconazole, ritonavir)</li>
                                <li>Other anticoagulants (except when switching)</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Use With Caution</h4>
                            <ul>
                                <li>NSAIDs (increased bleeding risk)</li>
                                <li>Antiplatelets (increased bleeding risk)</li>
                                <li>Strong P-gp inducers (reduced efficacy)</li>
                                <li>SSRIs/SNRIs (possible increased bleeding)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div id="rivaroxaban" class="tab-content">
            <div class="alert alert-danger">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>CONTRAINDICATED:</strong> CrCl &lt; 15 mL/min, significant liver disease with coagulopathy, prosthetic heart valves, antiphospholipid syndrome, active clinically significant bleeding.
                </div>
            </div>

            <div class="two-column">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-prescription-bottle-alt" style="color: var(--success);"></i>
                        <h3 class="card-title">Dosing Information</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Indication</th>
                            <th>Dose</th>
                        </tr>
                        <tr>
                            <td>NVAF Stroke Prevention</td>
                            <td>20mg once daily with food</td>
                        </tr>
                        <tr>
                            <td>NVAF (Reduced Dose)</td>
                            <td>15mg once daily if CrCl 15-50 mL/min</td>
                        </tr>
                        <tr>
                            <td>DVT/PE Treatment</td>
                            <td>15mg twice daily ×21 days, then 20mg once daily</td>
                        </tr>
                        <tr>
                            <td>Recurrent DVT/PE Prevention</td>
                            <td>20mg once daily (after ≥6 months treatment)</td>
                        </tr>
                        <tr>
                            <td>Hip Replacement</td>
                            <td>10mg once daily for 35 days</td>
                        </tr>
                        <tr>
                            <td>Knee Replacement</td>
                            <td>10mg once daily for 14 days</td>
                        </tr>
                    </table>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-exclamation-triangle" style="color: var(--warning);"></i>
                        <h3 class="card-title">Adverse Effects</h3>
                    </div>
                    <ul>
                        <li><strong>Common:</strong> Bleeding, anemia, nausea</li>
                        <li><strong>Uncommon:</strong> Hypersensitivity, thrombocytopenia, deranged LFTs</li>
                        <li><strong>Rare:</strong> Angioedema, eosinophilic pneumonia, anticoagulant-related nephropathy</li>
                    </ul>
                    <div class="alert alert-info">
                        <i class="fas fa-info-circle"></i>
                        <div>
                            <strong>REVERSAL:</strong> Andexanet alfa (Ondexxya®) for life-threatening or uncontrolled bleeding.
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Key Drug Interactions</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>Avoid With</h4>
                            <ul>
                                <li>Strong CYP3A4/P-gp inhibitors (ketoconazole, ritonavir)</li>
                                <li>Other anticoagulants (except when switching)</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Use With Caution</h4>
                            <ul>
                                <li>NSAIDs (increased bleeding risk)</li>
                                <li>Antiplatelets (increased bleeding risk)</li>
                                <li>Strong CYP3A4/P-gp inducers (reduced efficacy)</li>
                                <li>SSRIs/SNRIs (possible increased bleeding)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div id="warfarin" class="tab-content">
            <div class="alert alert-danger">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>CONTRAINDICATED:</strong> Pregnancy (except in specific circumstances), severe hypertension, recent hemorrhagic stroke, active bleeding, surgery with high bleeding risk.
                </div>
            </div>

            <div class="two-column">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-prescription-bottle-alt" style="color: var(--success);"></i>
                        <h3 class="card-title">Dosing Information</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Indication</th>
                            <th>Target INR</th>
                        </tr>
                        <tr>
                            <td>NVAF Stroke Prevention</td>
                            <td>2.0-3.0</td>
                        </tr>
                        <tr>
                            <td>DVT/PE Treatment</td>
                            <td>2.0-3.0</td>
                        </tr>
                        <tr>
                            <td>Recurrent DVT/PE Prevention</td>
                            <td>2.0-3.0</td>
                        </tr>
                        <tr>
                            <td>Mechanical Heart Valves</td>
                            <td>2.5-3.5 (depending on valve type/position)</td>
                        </tr>
                        <tr>
                            <td>TIA</td>
                            <td>2.0-3.0</td>
                        </tr>
                    </table>
                    <div class="alert alert-info">
                        <i class="fas fa-info-circle"></i>
                        <div>
                            <strong>INITIATION:</strong> Usually 5mg daily for 2-3 days, then adjusted based on INR. Elderly or frail may require lower starting dose.
                        </div>
                    </div>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-exclamation-triangle" style="color: var(--warning);"></i>
                        <h3 class="card-title">Adverse Effects</h3>
                    </div>
                    <ul>
                        <li><strong>Common:</strong> Bleeding, skin necrosis (rare, usually within first week)</li>
                        <li><strong>Uncommon:</strong> Purple toe syndrome, calciphylaxis</li>
                        <li><strong>Rare:</strong> Hepatotoxicity, hypersensitivity</li>
                    </ul>
                    <div class="alert alert-info">
                        <i class="fas fa-info-circle"></i>
                        <div>
                            <strong>REVERSAL:</strong> Vitamin K (phytonadione) orally or IV for severe bleeding; Prothrombin Complex Concentrate (PCC) for life-threatening bleeding.
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>Key Drug Interactions</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>Increase INR (Bleeding Risk)</h4>
                            <ul>
                                <li>Antibiotics (especially macrolides, quinolones)</li>
                                <li>Amiodarone, statins, fibrates</li>
                                <li>SSRIs, SNRIs</li>
                                <li>NSAIDs, aspirin</li>
                                <li>Allopurinol, cimetidine</li>
                            </ul>
                        </div>
                        <div>
                            <h4>Decrease INR (Thrombosis Risk)</h4>
                            <ul>
                                <li>Carbamazepine, phenytoin, rifampicin</li>
                                <li>St. John's Wort</li>
                                <li>Oral contraceptives</li>
                                <li>High vitamin K intake (leafy greens)</li>
                                <li>Chronic alcohol use</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="collapsible">
                <div class="collapsible-header" onclick="toggleCollapsible(this)">
                    <h3>INR Management</h3>
                    <i class="fas fa-chevron-down"></i>
                </div>
                <div class="collapsible-content">
                    <div class="two-column">
                        <div>
                            <h4>High INR Without Bleeding</h4>
                            <ul>
                                <li>INR 5.0-8.0: Omit 1-2 doses, consider vitamin K 1-2.5mg orally</li>
                                <li>INR >8.0: Omit doses, vitamin K 2.5-5mg orally</li>
                                <li>If high bleeding risk: Consider vitamin K even at lower INR levels</li>
                            </ul>
                        </div>
                        <div>
                            <h4>High INR With Bleeding</h4>
                            <ul>
                                <li>Minor bleeding: Hold warfarin, vitamin K 2.5-5mg orally/IV</li>
                                <li>Major bleeding: Hold warfarin, vitamin K 5-10mg IV slow infusion, PCC</li>
                                <li>Life-threatening: PCC, vitamin K 10mg IV, FFP if PCC unavailable</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div id="emergency" class="tab-content">
            <div class="emergency-banner">
                <i class="fas fa-exclamation-circle"></i>
                <div>
                    <strong>EMERGENCY SITUATION:</strong> Life-threatening bleeding requires immediate reversal of anticoagulation.
                </div>
            </div>

            <div class="two-column">
                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-tint" style="color: var(--danger);"></i>
                        <h3 class="card-title">Bleeding Management</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Anticoagulant</th>
                            <th>Reversal Agent</th>
                            <th>Dose</th>
                        </tr>
                        <tr>
                            <td>Apixaban/Rivaroxaban/Edoxaban</td>
                            <td>Andexanet alfa (Ondexxya®)</td>
                            <td>Bolus followed by infusion</td>
                        </tr>
                        <tr>
                            <td>Dabigatran</td>
                            <td>Idarucizumab (Praxbind®)</td>
                            <td>5g IV (2 × 2.5g)</td>
                        </tr>
                        <tr>
                            <td>Warfarin</td>
                            <td>Vitamin K + PCC</td>
                            <td>Vit K 5-10mg IV + PCC</td>
                        </tr>
                    </table>
                </div>

                <div class="card">
                    <div class="card-header">
                        <i class="fas fa-procedures" style="color: var(--warning);"></i>
                        <h3 class="card-title">Peri-procedural Management</h3>
                    </div>
                    <table class="info-table">
                        <tr>
                            <th>Anticoagulant</th>
                            <th>Low Bleeding Risk</th>
                            <th>High Bleeding Risk</th>
                        </tr>
                        <tr>
                            <td>Apixaban</td>
                            <td>Stop 24h before</td>
                            <td>Stop 48h before</td>
                        </tr>
                        <tr>
                            <td>Dabigatran</td>
                            <td>Stop 24h before</td>
                            <td>Stop 48-72h before</td>
                        </tr>
                        <tr>
                            <td>Edoxaban</td>
                            <td>Stop 24h before</td>
                            <td>Stop 48h before</td>
                        </tr>
                        <tr>
                            <td>Rivaroxaban</td>
                            <td>Stop 24h before</td>
                            <td>Stop 48h before</td>
                        </tr>
                        <tr>
                            <td>Warfarin</td>
                            <td>Stop 3-5 days before</td>
                            <td>Stop 5 days before</td>
                        </tr>
                    </table>
                </div>
            </div>

            <div class="card">
                <div class="card-header">
                    <i class="fas fa-exclamation-triangle" style="color: var(--danger);"></i>
                    <h3 class="card-title">Emergency Red Flags</h3>
                </div>
                <div class="card-container">
                    <div class="card">
                        <h4><i class="fas fa-brain" style="color: var(--danger);"></i> Neurological</h4>
                        <ul>
                            <li>Sudden severe headache</li>
                            <li>Confusion or altered consciousness</li>
                            <li>Focal neurological deficits</li>
                            <li>Seizures</li>
                        </ul>
                    </div>
                    <div class="card">
                        <h4><i class="fas fa-lungs" style="color: var(--danger);"></i> Respiratory</h4>
                        <ul>
                            <li>Hemoptysis</li>
                            <li>Dyspnea</li>
                            <li>Chest pain</li>
                        </ul>
                    </div>
                    <div class="card">
                        <h4><i class="fas fa-stomach" style="color: var(--danger);"></i> Gastrointestinal</h4>
                        <ul>
                            <li>Hematemesis</li>
                            <li>Malena</li>
                            <li>Severe abdominal pain</li>
                        </ul>
                    </div>
                    <div class="card">
                        <h4><i class="fas fa-kidney" style="color: var(--danger);"></i> Genitourinary</h4>
                        <ul>
                            <li>Macroscopic hematuria</li>
                            <li>Severe flank pain</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="alert alert-success">
                <i class="fas fa-check-circle"></i>
                <div>
                    <strong>PATIENT ADVICE:</strong> All patients on anticoagulants should carry an alert card and seek immediate medical attention for any uncontrolled bleeding.
                </div>
            </div>
        </div>
    </div>

    <footer class="footer">
        <div class="container">
            <div class="footer-content">
                <div class="footer-section">
                    <h3 class="footer-title">Quick Reference</h3>
                    <ul class="footer-links">
                        <li><a href="#">Dosing Guidelines</a></li>
                        <li><a href="#">Drug Interactions</a></li>
                        <li><a href="#">Monitoring Requirements</a></li>
                    </ul>
                </div>
                <div class="footer-section">
                    <h3 class="footer-title">Emergency</h3>
                    <ul class="footer-links">
                        <li><a href="#">Bleeding Management</a></li>
                        <li><a href="#">Reversal Agents</a></li>
                        <li><a href="#">Peri-procedural Care</a></li>
                    </ul>
                </div>
                <div class="footer-section">
                    <h3 class="footer-title">Resources</h3>
                    <ul class="footer-links">
                        <li><a href="#">NICE Guidelines</a></li>
                        <li><a href="#">BNF</a></li>
                        <li><a href="#">Patient Information</a></li>
                    </ul>
                </div>
            </div>
            <div class="copyright">
                <p>&copy; 2025 Oral Anticoagulation Quick Reference. Based on NICE CKS data. Last updated August 2025.</p>
            </div>
        </div>
    </footer>

    <script>
        function openTab(tabName) {
            // Hide all tab content
            const tabContents = document.querySelectorAll('.tab-content');
            tabContents.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all tabs
            const tabs = document.querySelectorAll('.nav-tab');
            tabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show the selected tab content
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to the clicked tab
            event.target.closest('.nav-tab').classList.add('active');
        }

        function toggleCollapsible(element) {
            element.closest('.collapsible').classList.toggle('active');
        }

        // Add search functionality
        document.querySelector('.search-box input').addEventListener('input', function(e) {
            const searchTerm = e.target.value.toLowerCase();
            const activeTab = document.querySelector('.tab-content.active');
            
            if (searchTerm.length > 2) {
                // In a real implementation, this would search through the content
                // For now, we'll just highlight the search term
                console.log('Searching for:', searchTerm);
            }
        });

        // Add smooth scrolling
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                document.querySelector(this.getAttribute('href')).scrollIntoView({
                    behavior: 'smooth'
                });
            });
        });

        // Add print functionality
        document.addEventListener('keydown', function(e) {
            if (e.ctrlKey && e.key === 'p') {
                e.preventDefault();
                window.print();
            }
        });
    </script>
</body>
</html>